R ROIVANT SCIENCES LTD
$28.33
| Market Cap | $20.28B |
| P/E Ratio | — |
| Forward P/E | -27.46 |
| Dividend Yield | — |
| Beta | 1.21 |
| 52W Range | $9.08 - $29.72 |
| # Hedge Funds | 3 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 3 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| David Einhorn DME Capital Management | 1.58% | $44.90M | 2,069,309 | Buy |
| Viking Global Investors Viking Global Investors | 0.37% | $139.82M | 6,443,191 | Reduce 72.69% |
| Polen Capital Management Polen Capital Management | 0.00% | $209.00K | 9,662 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 96 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Meghan FitzgeraldDirector | Sale | 70,000 | $27.45 | $1.92M | 26 Mar 2026 | 30 Mar 2026 |
| Venker EricPresident & Immunovant CEO | Sale | 200,000 | $28.24 | $5.65M | 17 Mar 2026 | 17 Mar 2026 |
| Epperly Melissa B, | Sale | 41,861 | $28.68 | $1.20M | 16 Mar 2026 | 16 Mar 2026 |
| Torti FrankPresident and Vant Chair | Sale | 587,390 | $27.51 | $16.16M | 23 Feb 2026 | 23 Feb 2026 |
| Torti FrankPresident and Vant Chair | Sale | 1,012,610 | $27.15 | $27.49M | 20 Feb 2026 | 23 Feb 2026 |
| Torti FrankPresident and Vant Chair | Sale | 1,400,000 | $27.42 | $38.39M | 19 Feb 2026 | 23 Feb 2026 |
| MANCHESTER KEITH S | Sale | 225,000 | $26.50 | $5.96M | 13 Feb 2026 | 13 Feb 2026 |
| MANCHESTER KEITH S | Sale | 150,784 | $26.49 | $3.99M | 13 Feb 2026 | 13 Feb 2026 |
| Venker EricPresident & Immunovant CEO | Sale | 200,000 | $26.49 | $5.30M | 13 Feb 2026 | 18 Feb 2026 |
| QVT Financial LP | Sale | 225,000 | $26.50 | $5.96M | 13 Feb 2026 | 13 Feb 2026 |
| QVT Financial LP | Sale | 150,784 | $26.49 | $3.99M | 13 Feb 2026 | 13 Feb 2026 |
| Gold Daniel Allen | Sale | 225,000 | $26.50 | $5.96M | 13 Feb 2026 | 13 Feb 2026 |
| Gold Daniel Allen | Sale | 150,784 | $26.49 | $3.99M | 13 Feb 2026 | 13 Feb 2026 |
| QVT Financial LP | Sale | 150,000 | $26.72 | $4.01M | 12 Feb 2026 | 13 Feb 2026 |
| MANCHESTER KEITH S | Sale | 150,000 | $26.72 | $4.01M | 12 Feb 2026 | 13 Feb 2026 |
| Gold Daniel Allen | Sale | 150,000 | $26.72 | $4.01M | 12 Feb 2026 | 13 Feb 2026 |
| QVT Financial LP | Sale | 275,000 | $26.76 | $7.36M | 12 Feb 2026 | 13 Feb 2026 |
| MANCHESTER KEITH S | Sale | 275,000 | $26.76 | $7.36M | 12 Feb 2026 | 13 Feb 2026 |
| Gold Daniel Allen | Sale | 275,000 | $26.76 | $7.36M | 12 Feb 2026 | 13 Feb 2026 |
| Gold Daniel Allen | Sale | 425,000 | $26.67 | $11.33M | 11 Feb 2026 | 13 Feb 2026 |
| QVT Financial LP | Sale | 425,000 | $26.67 | $11.33M | 11 Feb 2026 | 13 Feb 2026 |
| MANCHESTER KEITH S | Sale | 425,000 | $26.67 | $11.33M | 11 Feb 2026 | 13 Feb 2026 |
| Sukhatme MayukhPresident & CIO | Sale | 339,441 | $26.47 | $8.99M | 09 Feb 2026 | 11 Feb 2026 |
| Venker EricPresident & Immunovant CEO | Sale | 200,000 | $21.92 | $4.38M | 12 Jan 2026 | 14 Jan 2026 |
| Sukhatme MayukhPresident & CIO | Sale | 1,018,995 | $21.71 | $22.12M | 31 Dec 2025 | 31 Dec 2025 |
| Mayukh SukhatmePresident & CIO | Sale | 1,018,995 | $21.71 | $22.12M | 31 Dec 2025 | 31 Dec 2025 |
| Sukhatme MayukhPresident & CIO | Sale | 311,873 | $21.74 | $6.78M | 29 Dec 2025 | 31 Dec 2025 |
| Mayukh SukhatmePresident & CIO | Sale | 311,873 | $21.74 | $6.78M | 29 Dec 2025 | 31 Dec 2025 |
| Venker EricPresident & Immunovant CEO | Sale | 75,000 | $22.53 | $1.69M | 24 Dec 2025 | 29 Dec 2025 |
| Eric VenkerPresident & Immunovant CEO | Sale | 75,000 | $22.53 | $1.69M | 24 Dec 2025 | 29 Dec 2025 |
| Venker EricPresident & Immunovant CEO | Sale | 200,000 | $22.45 | $4.49M | 23 Dec 2025 | 29 Dec 2025 |
| Pulik RichardCFO | Sale | 146,731 | $22.39 | $3.29M | 23 Dec 2025 | 29 Dec 2025 |
| Pulik RichardCFO | Sale | 260,000 | $22.45 | $5.84M | 23 Dec 2025 | 29 Dec 2025 |
| Eric VenkerPresident & Immunovant CEO | Sale | 200,000 | $22.45 | $4.49M | 23 Dec 2025 | 29 Dec 2025 |
| Richard PulikCFO | Sale | 146,731 | $22.39 | $3.29M | 23 Dec 2025 | 29 Dec 2025 |
| Richard PulikCFO | Sale | 260,000 | $22.45 | $5.84M | 23 Dec 2025 | 29 Dec 2025 |
| MANCHESTER KEITH S | Sale | 155,076 | $23.02 | $3.57M | 17 Dec 2025 | 18 Dec 2025 |
| Gold Daniel Allen | Sale | 189,538 | $23.17 | $4.39M | 17 Dec 2025 | 18 Dec 2025 |
| QVT Financial LP | Sale | 189,538 | $23.17 | $4.39M | 17 Dec 2025 | 18 Dec 2025 |
| QVT Financial LP | Sale | 432,718 | $23.05 | $9.97M | 17 Dec 2025 | 18 Dec 2025 |
| Sukhatme MayukhPresident & CIO | Sale | 26,831 | $23.09 | $619.53K | 17 Dec 2025 | 19 Dec 2025 |
| MANCHESTER KEITH S | Sale | 189,538 | $23.17 | $4.39M | 17 Dec 2025 | 18 Dec 2025 |
| MANCHESTER KEITH S | Sale | 432,718 | $23.05 | $9.97M | 17 Dec 2025 | 18 Dec 2025 |
| Gold Daniel Allen | Sale | 155,076 | $23.02 | $3.57M | 17 Dec 2025 | 18 Dec 2025 |
| Gold Daniel Allen | Sale | 432,718 | $23.05 | $9.97M | 17 Dec 2025 | 18 Dec 2025 |
| QVT Financial LP | Sale | 155,076 | $23.02 | $3.57M | 17 Dec 2025 | 18 Dec 2025 |
| MANCHESTER KEITH S | Sale | 275,000 | $22.93 | $6.31M | 16 Dec 2025 | 18 Dec 2025 |
| Gold Daniel Allen | Sale | 642,282 | $23.08 | $14.82M | 16 Dec 2025 | 18 Dec 2025 |
| Gold Daniel Allen | Sale | 275,000 | $22.93 | $6.31M | 16 Dec 2025 | 18 Dec 2025 |
| QVT Financial LP | Sale | 642,282 | $23.08 | $14.82M | 16 Dec 2025 | 18 Dec 2025 |
| MANCHESTER KEITH S | Sale | 642,282 | $23.08 | $14.82M | 16 Dec 2025 | 18 Dec 2025 |
| QVT Financial LP | Sale | 275,000 | $22.93 | $6.31M | 16 Dec 2025 | 18 Dec 2025 |
| Gline MatthewCEO | Sale | 943,527 | $21.68 | $20.46M | 15 Dec 2025 | 17 Dec 2025 |
| Gline MatthewCEO | Sale | 566,116 | $21.68 | $12.27M | 15 Dec 2025 | 17 Dec 2025 |
| Gline MatthewCEO | Sale | 230,357 | $21.68 | $4.99M | 15 Dec 2025 | 17 Dec 2025 |
| Ramaswamy Vivek | Sale | 353,745 | $22.05 | $7.80M | 15 Dec 2025 | 15 Dec 2025 |
| Ramaswamy Vivek | Sale | 1,975,858 | $21.96 | $43.39M | 12 Dec 2025 | 15 Dec 2025 |
| Ramaswamy Vivek | Sale | 774,142 | $21.64 | $16.75M | 11 Dec 2025 | 15 Dec 2025 |
| Venker EricPresident & Immunovant CEO | Sale | 200,000 | $20.85 | $4.17M | 09 Dec 2025 | 11 Dec 2025 |
| Gold Daniel Allen | Sale | 175,000 | $20.24 | $3.54M | 19 Nov 2025 | 21 Nov 2025 |
| Gold Daniel Allen | Sale | 125,000 | $20.16 | $2.52M | 19 Nov 2025 | 21 Nov 2025 |
| Gold Daniel Allen | Sale | 150,000 | $20.20 | $3.03M | 19 Nov 2025 | 21 Nov 2025 |
| Gold Daniel Allen | Sale | 850,000 | $20.25 | $17.21M | 19 Nov 2025 | 21 Nov 2025 |
| MANCHESTER KEITH S | Sale | 175,000 | $20.24 | $3.54M | 19 Nov 2025 | 21 Nov 2025 |
| MANCHESTER KEITH S | Sale | 850,000 | $20.25 | $17.21M | 19 Nov 2025 | 21 Nov 2025 |
| QVT Financial LP | Sale | 150,000 | $20.20 | $3.03M | 19 Nov 2025 | 21 Nov 2025 |
| MANCHESTER KEITH S | Sale | 125,000 | $20.16 | $2.52M | 19 Nov 2025 | 21 Nov 2025 |
| MANCHESTER KEITH S | Sale | 150,000 | $20.20 | $3.03M | 19 Nov 2025 | 21 Nov 2025 |
| QVT Financial LP | Sale | 125,000 | $20.16 | $2.52M | 19 Nov 2025 | 21 Nov 2025 |
| Keith S ManchesterDirector | Sale | 125,000 | $20.16 | $2.52M | 19 Nov 2025 | 21 Nov 2025 |
| Daniel Allen GoldDirector | Sale | 125,000 | $20.16 | $2.52M | 19 Nov 2025 | 21 Nov 2025 |
| Daniel Allen GoldDirector | Sale | 150,000 | $20.20 | $3.03M | 19 Nov 2025 | 21 Nov 2025 |
| QVT Financial LPOther | Sale | 175,000 | $20.24 | $3.54M | 19 Nov 2025 | 21 Nov 2025 |
| QVT Financial LPOther | Sale | 850,000 | $20.25 | $17.21M | 19 Nov 2025 | 21 Nov 2025 |
| Keith S ManchesterDirector | Sale | 175,000 | $20.24 | $3.54M | 19 Nov 2025 | 21 Nov 2025 |
| Keith S ManchesterDirector | Sale | 150,000 | $20.20 | $3.03M | 19 Nov 2025 | 21 Nov 2025 |
| Keith S ManchesterDirector | Sale | 850,000 | $20.25 | $17.21M | 19 Nov 2025 | 21 Nov 2025 |
| Daniel Allen GoldDirector | Sale | 175,000 | $20.24 | $3.54M | 19 Nov 2025 | 21 Nov 2025 |
| Daniel Allen GoldDirector | Sale | 850,000 | $20.25 | $17.21M | 19 Nov 2025 | 21 Nov 2025 |
| Ramaswamy Vivek | Sale | 539,650 | $20.51 | $11.07M | 17 Nov 2025 | 17 Nov 2025 |
| Ramaswamy Vivek | Sale | 1,027,670 | $20.33 | $20.89M | 14 Nov 2025 | 17 Nov 2025 |
| Ramaswamy Vivek | Sale | 287,283 | $20.81 | $5.98M | 13 Nov 2025 | 17 Nov 2025 |
| Venker EricPresident & Immunovant CEO | Sale | 200,000 | $20.22 | $4.04M | 07 Nov 2025 | 07 Nov 2025 |
| Venker EricPresident & Immunovant CEO | Sale | 118,418 | $17.06 | $2.02M | 17 Oct 2025 | 17 Oct 2025 |
| Eric VenkerPresident & Immunovant CEO | Sale | 118,418 | $17.06 | $2.02M | 17 Oct 2025 | 17 Oct 2025 |
| Venker EricPresident & Immunovant CEO | Sale | 318,282 | $17.05 | $5.43M | 16 Oct 2025 | 17 Oct 2025 |
| Eric VenkerPresident & Immunovant CEO | Sale | 318,282 | $17.05 | $5.43M | 16 Oct 2025 | 17 Oct 2025 |
| Venker EricPresident & Immunovant CEO | Sale | 414,683 | $16.93 | $7.02M | 15 Oct 2025 | 17 Oct 2025 |
| Eric VenkerPresident & Immunovant CEO | Sale | 414,683 | $16.93 | $7.02M | 15 Oct 2025 | 17 Oct 2025 |
| Venker EricPresident & Immunovant CEO | Sale | 20,727 | $16.25 | $336.81K | 13 Oct 2025 | 14 Oct 2025 |
| Eric VenkerPresident & Immunovant CEO | Sale | 20,727 | $16.25 | $336.81K | 13 Oct 2025 | 14 Oct 2025 |
| Venker EricPresident & Immunovant CEO | Sale | 104,940 | $16.30 | $1.71M | 09 Oct 2025 | 14 Oct 2025 |
| Eric VenkerPresident & Immunovant CEO | Sale | 104,940 | $16.30 | $1.71M | 09 Oct 2025 | 14 Oct 2025 |
| Venker EricPresident & Immunovant CEO | Sale | 138,602 | $16.20 | $2.25M | 08 Oct 2025 | 08 Oct 2025 |
| Venker EricPresident & Immunovant CEO | Sale | 355,161 | $16.15 | $5.74M | 07 Oct 2025 | 08 Oct 2025 |
| Venker EricPresident & Immunovant CEO | Sale | 171,396 | $16.34 | $2.80M | 06 Oct 2025 | 08 Oct 2025 |
Frequently Asked Questions
What is ROIV stock price today?
ROIVANT SCIENCES LTD (ROIV) is currently trading at $28.33. The stock has a 52-week range of $9.08 to $29.72 and a market capitalization of $20.28B.
Is ROIV a good stock to buy in 2026?
ROIVANT SCIENCES LTD has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +183.0%. 3 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling ROIV stock?
There have been 96 insider transactions for ROIV in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has ROIV stock performed over the past year?
ROIVANT SCIENCES LTD (ROIV) has returned +183.0% over the past 12 months. The stock traded between $9.08 and $29.72 during this period, and is currently at $28.33.
Which hedge funds own ROIV (ROIVANT SCIENCES LTD)?
3 tracked hedge funds currently hold ROIV in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is ROIV's market cap and valuation?
ROIVANT SCIENCES LTD (ROIV) has a market capitalization of $20.28B. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is ROIV's revenue and profitability?
ROIVANT SCIENCES LTD reported revenue of $13.31M with net income of N/A and a profit margin of N/A. The stock has a beta of 1.21.
What sector is ROIV in and who are its biggest institutional holders?
ROIVANT SCIENCES LTD (ROIV) operates in the Healthcare sector. It is held by 3 tracked hedge funds. See the ownership table above for the complete list.